It occasionally occurs to Paul Sekhri that if they pull this off, his company will be on the front page of the New York Times and a lead story in just about every major news outlet on the planet. He tries not to dwell on it, though.
“I just want to be laser-focused on getting to that point,” Sekhri says, before acknowledging, “Yes, it absolutely crossed my mind.”
Sekhri, a longtime biopharma executive with tenures at Sanofi and Novartis, is now entering year three as CEO of eGenesis, the biotech that George Church protégé Luhan Yang founded to genetically alter pigs so that they can be used for organ transplants. He led them through one megaround and has just closed another, raising $125 million from 17 different investors to push the first-ever (humanized) pig to human transplants into the clinic.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 102,200+ biopharma pros reading Endpoints daily — and it's free.
"up" - Google News
March 02, 2021 at 07:03PM
https://ift.tt/30iCBzD
AbbVie tees up a biotech buyout after sizing up their Parkinson's drug spun out of Kevan Shokat's lab - Endpoints News
"up" - Google News
https://ift.tt/350tWlq
Bagikan Berita Ini
0 Response to "AbbVie tees up a biotech buyout after sizing up their Parkinson's drug spun out of Kevan Shokat's lab - Endpoints News"
Post a Comment